Microsoft Restores Microsoft 365 Services After Widespread Outage 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
CAMBRIDGE, Mass., May 08, 2017 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor conferences in May. Details are as follows:
Bank of America Merrill Lynch 2017 Health Care Conference
| Date: | Wednesday, May 17, 2017 | ||
| Forum: | Panel Discussion on Gene Therapy and Gene Editing | ||
| Time: | 4:40 p.m. ET | ||
| Location: | Las Vegas |
UBS Global Healthcare Conference
| Date: | Monday, May 22, 2017 | ||
| Forum: | Company Presentation and Breakout Session | ||
| Time: | 8:00 a.m. ET | ||
| Location: | New York |
A live webcast of the presentation will be available on the Investors & Media section of the Editas website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the presentation.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact Cristi Barnett Editas Medicine, Inc. (617) 401-0113 [email protected] Investor Contact Mark Mullikin Editas Medicine, Inc. (617) 401-9083 [email protected]
